계명대학교 의학도서관 Repository

Hemangiopericytomas in the Central Nervous System: A Multicenter Study of Korean Cases with Validation of the Usage of STAT6 Immunohistochemistry for Diagnosis of Disease

Metadata Downloads
Author(s)
Junjeong ChoiSung-Hye ParkShin Kwang KhangYeon-Lim SuhSang Pyo KimYoun Soo LeeHyun Seok KwonSeok-Gu KangSe Hoon Kim
Keimyung Author(s)
Kim, Sang Pyo
Department
Dept. of Pathology (병리학)
Journal Title
Annals of Surgical Oncology
Issued Date
2016
Volume
23
Issue
suppl.5
Keyword
MeningiomaTotal ResectionNuclear ExpressionSolitary Fibrous TumorFusion Transcript
Abstract
Background. Hemangiopericytoma (HPC) in the central
nervous system (CNS) is a rare disease with distinctive
biological/clinical characteristics compared with
meningioma.
Methods. Cases of HPCs of the CNS were collected, and
clinicopathological records were retrospectively reviewed
and analyzed. Immunohistochemistry (IHC) for proliferative
markers (Ki-67, PHH3) and STAT6 were performed.
Results. A total of 140 cases were collected, with mean
follow-up of 77 months (median 58.8 months; range 0.53–
540.5 months). 1-, 5-, 10-, and 20-year survival rates were
99.1, 94.0, 74.4, and 61.9 %, respectively. Thirty-nine
patients (27.9 %) had recurrent disease. Mean and median
times to recurrence were 62.9 and 47.3 months with 1-, 5-,
10-, and 20-year recurrence-free survival rates of 98.3,
78.3, 50.1, and 11.0 %, respectively. Thirteen patients
(9.3 %) developed extracranial metastases. No adjuvant
radiation therapy, higher histologic grades, failure of grosstotal
resection, and cases with gamma-knife surgery (GKS)
were factors associated with shorter disease-free survival
(log-rank test, p = 0.02, 0.00, 0.02, 0.00), among which
high histologic grade and cases with GKS were significant
in multivariable analysis. Strong nuclear STAT6 expression
was noted in HPCs in 62 cases of HPCs (60/62,
96.8 %), whereas diffuse weak positivity was demonstrated
in all meningioma cases.
Conclusions. The survival rate in patients with HPC of the
CNS is comparable to that of previously reported series.
Recurrence remains a critical clinical issue of the disease.
Identification of NAB2-STAT6 fusion transcript with surrogate
IHC marker is a valuable diagnostic tool in the
differential diagnosis of the disease.
Keimyung Author(s)(Kor)
김상표
Publisher
School of Medicine
Citation
Junjeong Choi et al. (2016). Hemangiopericytomas in the Central Nervous System: A Multicenter Study of Korean Cases with Validation of the Usage of STAT6 Immunohistochemistry for Diagnosis of Disease. Annals of Surgical Oncology, 23(suppl.5), 954–961. doi: 10.1245/s10434-016-5414-x
Type
Article
ISSN
1068-9265
Source
https://link.springer.com/article/10.1245%2Fs10434-016-5414-x
DOI
10.1245/s10434-016-5414-x
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/32720
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Pathology (병리학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.